baohuoside I: structure given in first source; isolated from the herb Epimedium davidii [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Epimedium | genus | A plant genus of the family BERBERIDACEAE which is used in DRUGS, CHINESE HERBAL. Members contain flavonol glycosides including epimedins, icariin and noricariin.[MeSH] | Berberidaceae | The Barberry plant family of the order Ranunculales, subclass Magnoliidae, class Magnoliopsida. The shrubs have spiny leaves.[MeSH] |
| Epimedium davidii | species | [no description available] | Berberidaceae | The Barberry plant family of the order Ranunculales, subclass Magnoliidae, class Magnoliopsida. The shrubs have spiny leaves.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 5488822 |
| CHEMBL ID | 560116 |
| CHEBI ID | 82619 |
| SCHEMBL ID | 4229321 |
| MeSH ID | M0169198 |
| Synonym |
|---|
| 2H44 |
| baohuoside i |
| chebi:82619 , |
| CHEMBL560116 , |
| 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one |
| icariside ii , |
| 113558-15-9 |
| 4h-1-benzopyran-4-one, 3-((6-deoxy-alpha-l-mannopyranosyl)oxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)- |
| 3,5,7-trihydroxy-4'-methoxyl-8-prenylflavone-3-o-rhamnopyranoside |
| icarlin ii |
| anhydroicaritin-3-o-alpha-l-rhamnopyranoside |
| 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone-3-o-alpha-l-rhamnopyranoside |
| 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone-3-o-rhamnopyranoside |
| 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4h-chromen-3-yl 6-deoxy-alpha-l-mannopyranoside |
| CS-3673 |
| SCHEMBL4229321 |
| AC-33977 |
| Q-100071 |
| baohuoside-i |
| HY-N0011 |
| icariin-ii;icariside-ii |
| DTXSID40150457 |
| 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-4h-chromen-4-one |
| AS-75062 |
| bdbm50503751 |
| AKOS037514560 |
| Q27156136 |
| 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-3-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one |
| icariin-ii |
| icariside-ii |
| 4h-1-benzopyran-4-one, 3-[(6-deoxy-alpha-l-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)- |
| AMY496 |
| 3,5,7-trihydroxy-4'-methoxyl-8-prenylflavone-3-o-rhamnopyranoside; 4h-1-benzopyran-4-one, 3-((6-deoxy-alpha-l-mannopyranosyl)oxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-; 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo- |
| A894345 |
| baohuoside i; anhydroicaritin; icariside ii |
| gtpl10686 |
| EX-A6795 |
| baohuosidei |
Baohuoside I is a flavonoid isolated from Epimedium koreanum Nakai and has many pharmacological activities. It is a potential anticancer drug for a variety of malignancies and has been approved for in vitro use.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Baohuoside I is a flavonoid isolated from Epimedium koreanum Nakai and has many pharmacological activities. " | ( Baohuoside I Inhibits the Proliferation of Hepatocellular Carcinoma Cells via Apoptosis Signaling and NF-kB Pathway. Jiang, D; Pang, B; Sun, Y; Wang, Y; Xiao, J, 2021) | 3.51 |
| "Baohuoside I is a potential anticancer drug for a variety of malignancies and has been approved for in vitro use. " | ( Preparation of a nanoscale baohuoside I-phospholipid complex and determination of its absorption: in vivo and in vitro evaluations. Jia, XB; Jin, X; Qian, Q; Sun, E; Tan, XB; Zhang, ZH, 2012) | 2.12 |
| "Baohuoside I is an effective anti-cancer drug currently used for a variety of cancers in vitro. " | ( A novel drug-phospholipid complex loaded micelle for baohuoside I enhanced oral absorption: in vivo and in vivo evaluations. Jia, XB; Jin, X; Sun, E; Tan, XB; Zhang, ZH; Zhu, FX, 2013) | 2.08 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To investigate the pharmacokinetic characteristics of icariside II after a single oral dose administration of YiGu Capsule in healthy -Chinese volunteers." | ( Pharmacokinetic study of icariside II after a single dose administration of YiGu capsule in healthy Chinese volunteers. Guo, RC; Liu, XY; Wei, CM; Yuan, GY; Zhang, R, 2013) | 0.39 |
| "To explore the pharmacokinetic properties of icariin (ICA) and icariside II (ICA II) following intragastric and intravenous administration in rats, a rapid and sensitive method by using ultra-performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) was developed and validated for the simultaneous quantification of ICA and ICA II in rat plasma." | ( Comparative Pharmacokinetics Study of Icariin and Icariside II in Rats. Cheng, T; Ding, Y; Lu, L; Zhang, T; Zhang, Y; Zhao, Y, 2015) | 0.42 |
| " In this paper, a co-friendly, fast pretreatment method with high extraction efficiency, based on the tailor-made deep eutectic solvent (DES) system, combined with ultra performance liquid chromatography-triple quadrupole tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination of icarrin and icarisid II in rat plasma samples, which can be further applied to comparative pharmacokinetic studies after oral administration of Herba Epimedii and icarrin monomer in rats, respectively." | ( Tailor-made deep eutectic solvents extraction combined with UPLC-MS/MS determination of icarrin and icarisid II in rat plasma and its comparative pharmacokinetic application. Feng, Q; Guo, H; Ma, C; Qin, F; Tong, L; Xiong, Z, 2021) | 0.62 |
The optimum process of Icraiin be hydrolyzed to Baohuoside I by cellulase is determined by Plackett-Burman design combined with CCD response surface methodology.
| Excerpt | Reference | Relevance |
|---|---|---|
| "To optimize the process of Icraiin be hydrolyzed to Baohuoside I by cellulase by Plackett-Burman design combined with Central Composite Design (CCD) response surface methodology." | ( [Optimization of process of icraiin be hydrolyzed to Baohuoside I by cellulase based on Plackett-Burman design combined with CCD response surface methodology]. Chen, HM; Dai, Y; Deng, Y; Hu, J; Kang, M; Song, CX, 2014) | 0.9 |
| "The optimum process of Icraiin be hydrolyzed to Baohuoside I by cellulase is determined by Plackett-Burman design combined with CCD response surface methodology." | ( [Optimization of process of icraiin be hydrolyzed to Baohuoside I by cellulase based on Plackett-Burman design combined with CCD response surface methodology]. Chen, HM; Dai, Y; Deng, Y; Hu, J; Kang, M; Song, CX, 2014) | 0.91 |
| " In this paper, a co-friendly, fast pretreatment method with high extraction efficiency, based on the tailor-made deep eutectic solvent (DES) system, combined with ultra performance liquid chromatography-triple quadrupole tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination of icarrin and icarisid II in rat plasma samples, which can be further applied to comparative pharmacokinetic studies after oral administration of Herba Epimedii and icarrin monomer in rats, respectively." | ( Tailor-made deep eutectic solvents extraction combined with UPLC-MS/MS determination of icarrin and icarisid II in rat plasma and its comparative pharmacokinetic application. Feng, Q; Guo, H; Ma, C; Qin, F; Tong, L; Xiong, Z, 2021) | 0.62 |
We enhanced the oral bioavailability of baohuoside I by reducing the particle size of the phospholipid complex to the nanometer range, thereby improving its potential for clinical application.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Poor bioavailability of prenylated flavonoids results from their poor intrinsic permeation and transporter-mediated efflux." | ( Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo). Chen, Y; Hu, M; Jia, XB; Zhao, YH, 2008) | 0.35 |
| " The in vitro absorption of baohuoside I and baohuoside I-phospholipid complexes of different sizes were compared using the Caco-2 cell culture model, and subsequently, the bioavailability of baohuosidel and its complexes were estimated in vivo." | ( Preparation of a nanoscale baohuoside I-phospholipid complex and determination of its absorption: in vivo and in vitro evaluations. Jia, XB; Jin, X; Qian, Q; Sun, E; Tan, XB; Zhang, ZH, 2012) | 0.97 |
| "We enhanced the oral bioavailability of baohuoside I by reducing the particle size of the phospholipid complex to the nanometer range, thereby improving its potential for clinical application." | ( Preparation of a nanoscale baohuoside I-phospholipid complex and determination of its absorption: in vivo and in vitro evaluations. Jia, XB; Jin, X; Qian, Q; Sun, E; Tan, XB; Zhang, ZH, 2012) | 0.94 |
| " The relative bioavailability of the micelles (AUC(0-∞)) compared with baohuoside I (AUC(0-∞)) was 533%, demonstrating great potential for clinical application." | ( A novel drug-phospholipid complex loaded micelle for baohuoside I enhanced oral absorption: in vivo and in vivo evaluations. Jia, XB; Jin, X; Sun, E; Tan, XB; Zhang, ZH; Zhu, FX, 2013) | 0.87 |
| " The aim of this work was to use Solutol®HS15 and Pluronic F127 as surfactants to develop novel mixed micelles to enhance the oral bioavailability of IS by improving permeability and inhibiting efflux." | ( Preparation and evaluation of icariside II-loaded binary mixed micelles using Solutol HS15 and Pluronic F127 as carriers. Hou, J; Jia, XB; Sun, E; Wang, J; Yan, HM; Yang, L; Zhang, ZH, 2016) | 0.43 |
| " In addition,the permeability coefficient of baohuoside Ⅰ in Caco-2 monolayer cells and the four intestinal organs( duodenum,jejunum,ileum and colon) was increased and the oral bioavailability was also improved after adding the suet oil to BS-DOC." | ( [Effect of processing excipient suet oil on formation and absorption of baohuoside Ⅰ-bile salt self-assembled micelles]. Gu, HM; Hou, J; Jia, XB; Li, J; Sun, E, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " By contrast, similar dosage schedules of B-1 did not significantly prolong survival of cardiac grafts." | ( Immunopharmacology and toxicology of the plant flavonoid baohuoside-1 in mice. Geng, L; Li, SY; Ping, G; Seow, WK; Thong, YH, 1994) | 0.29 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| apoptosis inducer | Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| glycosyloxyflavone | A member of the class of flavones having one or more glycosyl residues attached at unspecified positions. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 1.7000 | 0.0024 | 0.8512 | 1.7000 | AID977608 |
| Chain A, cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 1.7000 | 0.0024 | 0.8512 | 1.7000 | AID977608 |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | IC50 (µMol) | 16.7000 | 0.0031 | 2.1602 | 9.6000 | AID1515260 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 1.7000 | 0.0000 | 1.1843 | 9.6140 | AID1625385 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| chromatin | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| nucleus | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| chromosome, telomeric region | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| nucleus | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| nucleoplasm | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| transcription regulator complex | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| protein-containing complex | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| DNA repair complex | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| cellular_component | cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) |
| cytosol | cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID428313 | Reversal of P-gp-mediated multidrug resistance in human MCF7 cells assessed as assessed as increase in intracellular adriamycin accumulation at 5 uM incubated 2 hrs before adriamycin challenge by spectrophotometry | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 | Synthesis and antimultidrug resistance evaluation of icariin and its derivatives. |
| AID1625385 | Inhibition of recombinant human PDE5A1 catalytic domain (535 to 860 residues) expressed in baculovirus infected sf9 cells using [3H]cGMP as substrate incubated for 15 mins by liquid scintillation counting method | 2016 | Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15 | PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design. |
| AID1515260 | Inhibition of LSD1 (unknown origin) by fluorescence assay | 2019 | Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2 | Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2006 | The Journal of biological chemistry, Jul-28, Volume: 281, Issue:30 | Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (0.65) | 18.7374 |
| 1990's | 4 (2.61) | 18.2507 |
| 2000's | 13 (8.50) | 29.6817 |
| 2010's | 92 (60.13) | 24.3611 |
| 2020's | 43 (28.10) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (0.65%) | 5.53% |
| Reviews | 5 (3.25%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 148 (96.10%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||